MS
Therapeutic Areas
Mallinckrodt Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TERLIVAZ® (terlipressin) | Hepatorenal Syndrome Type 1 (HRS-1) | Approved |
| Stannsoporfin (INH-001) | Prevention of severe hyperbilirubinemia in newborns | Phase 3 |
| StrataGraft® | Thermal burns containing intact dermal elements | Approved |
| Acthar® Gel | Multiple autoimmune/inflammatory conditions (e.g., MS exacerbations, nephrotic syndrome) | Approved |
| Ofirmev® | Pain and fever | Approved |
| Amitiza® | Opioid-induced constipation, Chronic idiopathic constipation | Approved |
| Xartemis® XR | Pain | Approved |
| Therakos® platform | Cutaneous T-cell lymphoma (via ECP) | Approved/Procedure |
Leadership Team at Mallinckrodt Pharmaceuticals
S(
Sigurdur (Siggi) Olafsson
Former President and Chief Executive Officer
MC
Mark C. Trudeau
Former President and Chief Executive Officer
SJ
Steven J. Romano, M.D.
Executive Vice President and Chief Scientific Officer
G(
George (J.R.) Reichenbach
Interim Principal Financial Officer
HM
Hugh M. O'Neill
Senior Vice President, Chief Commercial Officer - Autoimmune & Rare Diseases
JR
James R. Sulat
Former Senior Vice President, General Counsel and Secretary
DY
David Y. Norton
Former Senior Vice President, Chief Strategy and Business Development Officer
DM
Daniel M. Jorgensen, M.D., M.P.H., M.B.A.
Senior Vice President, Clinical Development and Medical Affairs
MK
Matthew K. Harbaugh
Former Senior Vice President, Chief Financial Officer
A(
Angela (Angi) L. Robinson
Vice President, Chief Compliance Officer